Pegilodecakin Uses, Dosage, Side Effects and more
Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
| Trade Name | Pegilodecakin |
| Generic | Pegilodecakin |
| Pegilodecakin Other Names | Pegilodecakin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
